Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma
Alvaro J. Alencar, Craig H. Moskowitz
Abstract
Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01751 Journal of Clinical Oncology - published online before print January 12, 2021 PMID: 33434059 Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma Alvaro J. Alencar , MD1xAlvaro J. AlencarSearch for articles by this author and Craig H. Moskowitz, MD1xCraig H. MoskowitzSearch for articles by this author Show More 1Division of Hematology, Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL https://doi.org/10.1200/JCO.20.01751 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyContextKey ObjectiveIs chimeric antigen receptor (CAR) T-cell therapy replacing autologous stem cell transplantation (ASCT) in the management of patients with relapsed diffuse large B-cell lymphoma (DLBCL)?Knowledge GeneratedCAR T-cell therapy has impressive activity, but failures are common, and logistic challenges still limit its use. ASCT remains a curative intervention in patients with chemosensitive disease, particularly those with complete metabolic response after salvage.RelevanceThe future of management of relapsed DLBCL lies in accurate patient selection and better integration of novel techniques with well-established therapeutic options.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTAutologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin LymphomaThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Alvaro J. AlencarConsulting or Advisory Role: Celgene, AbbVie/Genentech, Kite Pharma, Spectrum Pharmaceuticals, Amgen, Karyopharm TherapeuticsSpeakers’ Bureau: Kite Pharma (I)Research Funding: Loxo (Inst)Open Payments Link: https://openpaymentsdata.cms.gov/physician/1171980Craig H. MoskowitzConsulting or Advisory Role: Merck Sharp & Dohme, Molecular Templates, Takeda, AstraZeneca, IncyteResearch Funding: AstraZeneca (Inst), Merck Sharp & Dohme (Inst)No other potential conflicts of interest were reported.